December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.